Search for Associate Director for Clinical Research and Holden Chair
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
ABOUT THIS POSITION
1
CHANGING MEDICINE. CHANGING LIVES.
Search for Associate Director
for Clinical Research and
Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 2 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
ABOUT THIS POSITION
3
CHANGING MEDICINE. CHANGING LIVES.
Contents
About this search.........................................4
Holden Comprehensive
Cancer Center...............................................9
History....................................................................10
Today......................................................................14
Holden Family Support.....................................16
Organization and Leadership.........................18
Research Programs........................................... 22
Cores and Shared Resources......................... 29
University of Iowa Health Care.............45
UI Carver College of Medicine..............59
UI Hospitals and Clinics..........................75
Health Sciences Campus....................... 85
University of Iowa..................................... 91
The Iowa City Community....................97
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
4 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
About this
Position
The Holden Comprehensive Cancer Center (HCCC) at The
University of Iowa is seeking an outstanding clinician-
investigator to serve as the associate director for clinical
research and to direct the Roland W. Holden Family Program
in Experimental Therapeutics. The successful candidate will
also serve as the Holden Family Chair.
As the associate director for clinical research The ideal candidate will also have familiarity
of an NCI-designated Comprehensive Cancer with both laboratory and clinical aspects of
Center Center, the successful candidate will be cancer experimental therapeutics and drug
expected to provide leadership and integrate development, investigator-initiated and
all therapeutically related translational and cooperative group clinical trials, knowledge
clinical cancer research taking place within the of regulatory guidelines and procedures, and
institution, and also contribute to establishing familiarity with NCI-designated Cancer Center
external collaborations. The successful operations.
candidate will have an MD or MD/PhD degree,
with a strong record of publication and funding, The successful candidate will have their
including external peer-reviewed funding, in primary academic appointment in a clinical
clinical cancer research and experimental department at The University of Iowa Carver
therapeutics. Experience in a multi-disciplinary College of Medicine. A leadership role in the
setting, experience in program development Division of Hematology, Oncology, and Blood
in an academic medical center, commitment and Marrow Transplantation in the Department
to diversity in the workplace, and excellent of Internal Medicine is available based on the
communication and leadership skills are interest and qualification of the applicant.
required.
ABOUT THIS POSITION
5
CHANGING MEDICINE. CHANGING LIVES.
The HCCC received NCI-designation In addition, a number of cancer type
in 1999 and comprehensive specific muliti-disciplinary oncology
designation from the NCI in 2000. groups (MOGs) have been developed
It has undergone successful and are active in both clinical and
competitive renewal of this research efforts. The HCCC has a
designation twice since that time. robust Clinical Trials Support Core
The HCCC is organized in two that includes 35 full-time staff who
different dimensions. The formal assist in protocol development,
research programs of the HCCC are management, and the conduct of
based on scientific discipline and trials. The Clinical Trials Support
include cancer immunology and Core also supports bedside to bench
immunotherapy, cancer signaling and translational research including
experimental therapeutics, cancer the prospective clinical registries of
genetics and gell growth, tumor the HCCC. These are known as the
imaging, free radical cancer biology, Molecular Epidemiology Resources
and cancer epidemiology. (MERs), work closely to the HCCC
Tissue Procurement Core and
biobanks, and have enrolled over
4,500 subjects in a variety of cancer
types.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
6 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Role and Responsibilities
The Holden Comprehensive Cancer Center associate
director for clinical research will lead the clinical and
translational research efforts of the cancer center. This
includes providing administrative oversight of the clinical
research infrastructure, clinical research collaborative
efforts, clinical and translational research pilot grant
programs, serving as a mentor to junior investigators
and determining use of funds dedicated to clinical
cancer research. The associate director will serve on the
HCCC Leadership Committee and Research Executive
Committee, and will chair the Clinical Research Leadership
Committee.
The associate director for clinical research will supervise
the assistant directors for clinical research. Together,
they will oversee the Clinical Trials Support Core, Clinical
Trials Development, Support and Monitoring Office,
Protocol Review Committee and the Data and Safety
Monitoring Committee as well as the 12 cancer-specific
multidisciplinary oncology groups.
ABOUT THIS POSITION
7
CHANGING MEDICINE. CHANGING LIVES.
Endowed Positions and Programs
The Holden Endowment to support Experimental Therapeutics was established in 2000 to support
research geared towards advancing knowledge of cancer and application of this knowledge to the
discovery and development of new cancer therapeutics. This research is expected to include the
design and synthesis of novel chemicals and testing of active agents in humans.
The endowment consists of two components.:
Holden Family Chair
This fund supports a chair in the University of Iowa Roy J. and Lucille A. Carver College of Medicine for
the Director of the Roland W. Holden Family Program for Experimental Cancer Therapeutics.
Roland W. Holden Family Program for Experimental Cancer Therapeutics
The Program itself is supported by the Roland W. Holden Family Endowed Fund.
Support for the clinical research infrastructure of the Holden Comprehensive Cancer Center comes
from other sources so support from the Roland W. Holden Family Program for Experimental Cancer
Therapeutics can be directed towards specific research projects in Experimental Cancer Therapeutics.
Dr. Raymond Hohl was the founding Director of the Program. Dr. Hohl’s efforts focused on the RAS
pathway and novel approaches to targeting the isoprene intermediates in the cholesterol biosynthetic
pathway. His efforts included extensive collaborations with synthetic chemists in the Department of
Chemistry as well as a broad range of investigators across the Cancer Center. The next recipient of the
Holden Chair will be expected to leverage the infrastructure and contributions developed by Dr. Hohl
while also applying their own research expertise to goals of the Holden Program in Experimental
Therapeutics.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
8 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Search Committee
K A RL W. T H O M A S , M D GA RY ROS EN T HA L , MD
Chair Director, Iowa Institute for Clinical and
Executive Vice Chair, Department of Internal Translational Science
Medicine Professor of Internal Medicine
Professor of Internal Medicine
karl-thomas@uiowa.edu gary-rosenthal@uiowa.edu
MO H A M M E D M . M I L H E M , M B BS YAT IN V YA S , MD, PHD
Deputy Director for Clinical Cancer Care, Director, Division of Pediatric Hematology and
Holden Comprehensive Cancer Center Oncology
Associate Professor of Internal Medicine Professor of Pediatrics
mohammed-milhem@uiowa.edu yatin-vyas@uiowa.edu
K I M B E RLY K . L E S L I E , M D JA MES C. WA L K ER, PHD
Chair and Department Executive Officer, Associate Vice President for Research
Department of Obstetrics and Gynecology
james-walker@uiowa.edu
kimberly-leslie@uiowa.edu
MI C H A E L H E N RY, P H D B RIA N K . L IN K , MD
Deputy Director for Research, Holden Director, Clinical Trials Support Core, Holden
Comprehensive Cancer Center Comprehensive Cancer Center
Associate Professor of Molecular Physiology Professor of Internal Medicine
and Biophysics
michael-henry@uiowa.edu brian-link@uiowa.edu
ALIASGER SALEM, PHD PA LOMA H. G IA N GRA N DE , PHD
Lyle and Sharon Bighley Professor of Associate Professor of Internal Medicine
Pharmaceutical Sciences and Leader, Cell
Signaling and Experimental Therapeutics paloma-giangrande@uiowa.edu
Program, Holden Comprehensive Cancer
Center
aliasger-salem@uiowa.edu
About the Holden Comprehensive Cancer Center
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
10 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Holden
Comprehensive
Cancer Center
Efforts to form a comprehensively organized program
in cancer began in the 1970s when former Dean John
W. Eckstein, MD charged the College of Medicine’s
Committee on Cancer with the responsibility of reviewing
and developing research, demonstration, and education
programs in cancer.
Richard L. DeGowin, MD began the effort by Since 1980, the Cancer Center has experienced
working with faculty members in the College’s tremendous growth and achieved the highest
of Medicine, Nursing, Dentistry, Pharmacy level of recognition status given by the National
and Liberal Arts and Sciences and after much Cancer Institute—comprehensive—in
work, a plan was implemented for the creation 2000. To reflect this achievement, and in
of a more organized cancer program at the recognition of a landmark, $25 million gift
university. Following presentation to the from four generations of the Holden family of
Board of Regents, State of Iowa, in 1980 the Williamsburg, Iowa, the Cancer Center was
new program was conferred special “center renamed the Holden Comprehensive Cancer
designation, ” and DeGowin became the Cancer Center.
Center’s first director.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
11
CHANGING MEDICINE. CHANGING LIVES.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
12 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Timeline
1980
The University of Iowa cancer program is conferred special
“center” status by the Iowa Board of Regents.
Richard L. DeGowin named director.
1981 1998
George J. Weiner, MD, appointed
The Cancer Center received a three-year CancerCenter director of the Cancer Center.
Support Grant from the National Cancer Institute.
1993
The grant was not renewed.
With the support of a generous gift from the Pappajohn
family of Des Moines, the John and Mary Pappajohn Clinical
Cancer Center opened, providing a multidisciplinary
approach to state-of-the-art patient care. This effort was
coordinated by Richard D. Williams, MD.
1988
University of Iowa, University of
Iowa College of Medicine and 1995
1986 University of Iowa Hospitals and
Clinics leadership develop plans University of Iowa
for expanded laboratory research President Mary Sue
Cancer Information initiatives and construction of new
Service opens. Coleman, PhD, College
clinical care facilities. of Medicine Dean Robert
Kelch, MD and R. Edward
Howell, director and
1994 CEO of the UI Hospitals
and Clinics—all recently
appointed—reinforce
The NCI provided funds for restructuring the Cancer institutional commitments
Center through a P20 Cancer Center Planning Grant. to support and strengthen
This effort was led by Richard G. Lynch, MD. the Cancer Center.
Robert B. Wallace, MD, was appointed as director of the
Cancer Center.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
13
CHANGING MEDICINE. CHANGING LIVES.
1999
The Cancer
Center
submitted
a Cancer 2002
Center
Support Completion of
the new Roland
2007 2011 2014
Grant
application and Ruby Holden New image guided NCI- Dr, Raymond Hohl,
to the Cancer Research center for radiation designation as a associate director
National Laboratories. therapy opens. comprehensive for clinical research
Cancer cancer center and Holden Chair,
Institute. Iowa receives its Renewal of $11.9 following moves to Penn State
first Specialized million Specialized competitive University as director
Program of Research Program of review with of the Penn State
Excellence (SPORE) Excellence (SPORE) a score of Hershey Cancer
Grant—the Iowa/ grant for lymphoma “outstanding.” Center.
Mayo Lymphoma research.
SPORE.
2001 2008
Center receives National Outstanding Achievement Award from the
Commission on Cancer for providing superior care to patients and
Construction
families.
begins on
the Holden
Center Iowa teams up with several agencies to provide housing,
Cancer
Research
Laboratories
2005 transportation and medical assistance to cancer patients devastated
by the floods and tornadoes in Iowa.
in the new
NCI-designation as a
Medical
comprehensive cancer center
Education
renewed following competitive
and Research
review.
Facility.
2004
Iowa Consortium for Comprehensive Cancer Control launched,
providing coordinated cancer control for Iowans.
2000
The National Cancer Institute conducts a site visit of the Cancer Center in January.
The National Cancer Institute confers “NCI-designated Cancer Center” status in July.
The Cancer center receives a landmark, $25 million gift from four generations of the Holden family
of Williamsburg, Iowa and is renamed Holden Cancer Center.
The Roland W. Holden Family Program for Experimental Therapeutics was established and
Dr. Raymond Hohl, was named the Roland W. Holden Family Chair for Experimental Cancer
Therapeutics.
Holden Cancer Center achieves the highest level of recognition—comprehensive status given by
the National Cancer Institute and is renamed Holden Comprehensive Cancer Center.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
14 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
The Center Today
Holden Comprehensive Cancer • Free Radical and Cancer Biology
Center remains dedicated to bringing • Tumor Imaging While research is conducted in
world-class research and cancer care laboratories throughout the University
to Iowa, the Midwest, and beyond. • Cancer Epidemiology of Iowa campus, the Roland and Ruby
• Cancer Genomics and Cell Growth Holden Cancer Research Laboratories
The matrix center now spans the allow the Center to integrate many
University of Iowa and includes Each of these programs is focused on researchers in close proximity to each
approximately 180 formal Cancer a cancer-relevant scientific discipline, other.
Center members and many additional is translational, and includes
physicians, investigators and other members from several colleges and Outreach to the people of Iowa is
staff from 36 related university diverse backgrounds. an important component of the
departments and six colleges, as well Center’s activities. Holden provides
as the University of Iowa Hospitals The Holden Comprehensive information through its Cancer
and Clinics and the University of Iowa Cancer Center is also organized Information Service to patients, their
Children’s Hospital. based on cancer type through the families, and health professionals.
Multidisciplinary Oncology Groups In addition, there are a number of
Research at Holden Comprehensive (MOGs). The MOGs are responsible cancer support groups that meet
Cancer Centeris organized into six for coordinating multidisciplinary regularly in local communities. The
research programs: clinical care through tumor boards, Center also includes many patients
• Cancer Immunology and multidisciplinary clinics, etc. in its active program of Phase I and
Immunotherapy They also serve as the focus for Phase II clinical trials.
development of innovative clinical
• Cancer Signaling and Experimental trials.
TherapeuticsABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
15
CHANGING MEDICINE. CHANGING LIVES.
Holden Comprehensive Cancer Center Statistics
C LI N I C AL AC T I V I T Y C L I N ICA L FACIL IT IES A N D S PACE RES EA RCH A N D S PACE
154,232 37 $74.2
Total visits to UI Health Care with Exam rooms in Million in total annual cancer-related
primary diagnosis of cancer the Cancer Clinic research funding
31,372 3 $44
Unique patients treated with Consult rooms in Million in current endowments in
primary diagnosis of cancer the Cancer Clinic support of the mission
48,288 2 221
Total visits in the Treatment Rooms in Open clinical trials for
cancer clinic the Cancer Clinic cancer patients
3,615 32 3,289
Admissions for patients with a Chairs in the Patients enrolled in
primary diagnosis of cancer chemotherapy suite clinical trials
3,800 8 189
New cancer patients diagnosed Beds in the Cancer Center members in 36
at UI Hospitals and Clinics chemotherapy suite departments and six colleges
20,400 >146,000 6
Radiation oncology Net square feet of Research Programs
treatments delivered clinical oncology space in the Center
14,639 74 10
Chemotherapy sessions Inpatient beds on three units Core Facilities supported by the
delivered with a dedicated pharmacy Cancer Center
117 14 4
Bone marrow transplants Beds in the Adult Leukemia and Core Facilities supported by the
(106 adult, 11 pediatric) Bone Marrow Transplant Unit Lymphoma SPORE grant
8,283 31 33,953
Contacts to the Cancer Bone bone marrow transplant and Square feet of research space in
Information Service hematology oncology beds Holden Research LaboratoriesUNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
16 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Holden Family Support
Through years of visionary support for the Holden RES EA RCH
Comprehensive Cancer Center at the University of Iowa,
Cutting-edge research, new cancer investigators, and
the Holden family has helped establish the UI as a major
studies that have translated laboratory discoveries into
center for cancer research, patient care, and education.
innovative patient treatment options.
The Holden Comprehensive Cancer Center was so named
in 2000, when four generations of the Holden family made
The Clinical Trials Support Core, which include trials
a landmark gift of $25 million to support what was then the
that come from our own labs, collaboration with other
University of Iowa Cancer Center. In the 13 years since the
cancer centers, and partnerships with biotechnology and
Holden gift, world-class research scientists, physicians,
pharmaceutical companies. Treatments that would not
and other health care professionals have worked tirelessly
otherwise be available in Iowa are available to our patients
to advance research that helps prevent, detect, and treat
because of these trials.
cancer for our patients.
PAT IEN T S ERV ICES A N D CA RE
The Holden family gift was made in honor of the late
Roland W. Holden, who died in 1995. Holden founded The UI Palliative Care Service—a team of nurses, social
Holden Foundation Seeds Inc., a corn seed research and workers, chaplains and physicians that assists terminally ill
genetics company based in Williamsburg, Iowa, 30 miles patients and their families. This interdisciplinary program
west of Iowa City, in 1937. His family chose to celebrate his provides emotional and spiritual support and help in
legacy by supporting research and treatment that may planning for care outside the hospital, as well as pain
eventually cure the disease that took his life. control and symptom management.
Contributors to the $25 million gift included Ruby Holden;
Ronald, Arlene, and Kathy Holden; Susan and David
McCurry; Karol Holden; Mary Ann and Curtis Blythe; and
the Roland and Ruby Holden Foundation.
The gift, one of the largest received for UI Health Care
initiatives, has supported a full range of critical programs
within the Holden Comprehensive Cancer Center, including:ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
17
CHANGING MEDICINE. CHANGING LIVES.
The Holden family of Williamsburg, Iowa.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
18 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
HCCC Executive Board
Jean Robillard, MD
Vice President for Medical Affairs
Organization Director
George Weiner, MD
Deputy Director for Research
Michael Henry, PhD
Executive Director of Development Internal and External
Sarah Russett, UI Foundation Advisory Boards
Associate Director for
Clinical Research
Assistant Director for Assistant Director for Clinical
Multidisciplinary Clinical Research Research Services
Mohammed Milhem, MBBS Daniel Vaena, MD
Carlie Etscheidt (Administrative Director)
Multidisciplinary Multidisciplinary Clinical Trials
Oncology Groups Oncology Group Protocol Review and Support Core
Research Support
Carmen Tilman Coordinator Monitoring Brian Link, MD
(Board Coordinator) Julianna Kennedy (Director)
Protocol Clinical Trials Clinical Trials
Development and DSM Chair Data Management Clinical Trials Informatics Support
Regulatory Manager Translational Systems Specialist
Monitoring Chair Daniel Berg, MD Manager Research Manager
Michael Goodheart, MD Mary Schall Marian Andersen Inez Mattke
Laura Jacobus
Protocol Clinical Research Regulatory Associate Translational Research
Specialists T. Kriegel Assistants
Development and M. Arnold (90%) C. Hamlin
Monitoring Manager R. Arthur Financial Analyst A. Janoski
Gary Rick M. Frees B. Franzwa T. Knutson
J. Geick Miller J. Gallagher M. Brumm
Protocol Writer and K. Parrott S. Rosazza
Safety Officer J. Wegmann Cancer and Leukemia
M. Rosenquist P. Zehr Group B Coordinator Biospecimen Collection
C. Halvorsen Technician
Protocol Management Clinical Research J. Cook-Granroth
Assistant Associates National Surgical
A. Childs S. Gillen Adjuvant Breast Data Manager
J. Schlabaugh and Bowel Project S. Grimm (temp)
Coordinator
Clinical Research C. Robertson
Assistants
J. de la Garza Clerk III
S. Teahen L. Johnson (75%)
Clinical and Data
Management Research
Specialist
A. Tricot
Data Managers
A. Marlof
A. Schultz
A. Capper
A. Ulin
Medical Assistant II
J. LarsonABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
19
CHANGING MEDICINE. CHANGING LIVES.
Leadership
George J. Weiner, MD
Director, Holden Comprehensive Cancer Center
George Weiner MD, is an active translational cancer investigator who has been on the faculty at
the University of Iowa since 1989. He is Director of the Holden Comprehensive Cancer Center
(HCCC), Professor of Internal Medicine, C.E. Block Chair of Cancer Research, and a faculty
member in the Interdisciplinary Program in Immunology at the University of Iowa.
Administratively, Dr. Weiner was appointed Director of the HCCC on December 1, 1998, and
led the HCCC to recognition as an NCI-designated comprehensive cancer center in 2000.
This designation was renewed in 2005 and 2011. Dr. Weiner was served in a number of
leadership positions at the state and national level including the following.
• Chair, NCI subcommittee A also known as the Cancer Center Parent Committee (2007-
2009). He chaired site visits for the NCI at 8 cancer centers.
• Vice President / President Elect, Association of American Cancer Institutes (2013-present).
• President, Iowa Cancer Consortium (2003-present)
• Chair, Governmental Affairs Committee, American Society of Hematology
(2008-2012)
• Co-Chair, Science Policy and Governmental Affairs Committee,
American Association for Cancer Research (2012-present)
• Chair of External Advisory Boards for 3 NCI designated cancer
centers.
• PI of the Iowa/Mayo Lymphoma SPORE (2002-present)
• Co-Chair, C-Change initiative on Comprehensive Cancer Control
• Member, CTAC - NCI Clinical and Translational Research
Advisory Committee (2012-present)
Dr. Weiner’s research focuses on understanding the
mechanisms of action of anti-cancer monoclonal antibodies,
and on development of novel approaches to immunotherapy
of lymphoma. He has been continually funded by the
NCI since 1991. Dr. Weiner’s research extends from basic
laboratory investigation to clinical trials. He is the holder of
four patents with a number of others pending, and was the
first to demonstrate Toll Like Receptor 9 agonists could be used
successfully as immune adjuvants in tumor immunization. He
also has made major contributions to our understanding of the
mechanisms of action responsible for the anti-tumor activity of
monoclonal antibodies.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
20 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
GAI L A . BI SHOP, P H D E L I Z A B E TH CHRIS CHIL L ES , PHD MICHA EL D. HEN RY, PHD
Associate Director for Basic Research Associate Director for Population Science Deputy Director for Research
Dr. Gail Bishop, appointed associate Elizabeth Chrischilles, the Marvin A. Dr. Henry serves as deputy director
director for basic research in 2004, and Rose Lee Pomerantz Chair in for research. This important position
advises the HCCC director on Public Health, and director, Health is supported by institutional funds.
issues related to the basic science Effectiveness Research Center, was He has focused his efforts on new
programs, including allocation of appointed as the HCCC associate initiatives and special projects
research space, and resources, director for population sciences in including developing the overall
and membership in the research 2007. Molecular Oncology Initiative. A
programs. Bishop’s role is to major focus of this effort is improving
coordinate and assure the quality of In this role, Dr. Chrischilles is tissue collection, annotation and
the basic science research programs charged with enhancing the HCCC’s distribution through the Tissue
of the Center, to provide advice on population science activities including Procurement Core/Biospecimens
faculty recruitment in basic science epidemiology, prevention, community Initiative including identification of a
areas, formulate program policy, and health, public policy and outcomes software package described above.
overseeing the use of basic science analysis. She provides leadership to He has also worked on integrating
shared facilities in consultation with the research programs considered the molecular pathology group
the associate director for research primarily population science into the HCCC. This has included
infrastructure. Bishop works with programs and provides advice and promoting meetings of the director
the HCCC director to encourage guidance to HCCC members relative of the Molecular Pathology Division,
translation of basic advances to to population science activities Dr. Aaron Bossler, with MOGs and
the clinic. As associate director for within the HCCC. She also has medical oncologists to assess
basic science, Dr. Bishop reviews all the responsibility of encouraging ongoing needs for new actionable
applications for HCCC membership. population science activities in the molecular tests. In late 2013, the
She is a member of both the HCCC other research programs. molecular pathology group received
Executive Committee and Associate CLIA certification for sequencing
Director’s Committee. The research Dr. Chrischilles is a member of the capabilities of 50 cancer-related
programs that are primarily focused HCCC Executive Committee and the genes that are now being used
on basic cancer research (Cancer Associate Directors Committee. for both clinical care and clinical
Genomics and Cell Growth, and research. Dr. Henry also chairs
Free Radical Cancer Biology) report the monthly Research Executive
formally to her. Dr. Bishop also Committee meeting which includes
provides advice related to the basic all of the Program Leaders and Co-
laboratory research taking place in Leaders.
the other four research programs.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
21
CHANGING MEDICINE. CHANGING LIVES.
DAVI D M . LU B A RO F F, P H D M O HA MMED M. MIL HEM, MD CHRIS TOPHER L AUB EN T H AL , MBA
Associate Director for Research Infrastructure Deputy Director for Clinical Cancer Services Associate Director for Administration
David Lubaroff, Ph.D., has served Dr. Milhem has been a faculty The associate director for
as associate director for research member at the University of Iowa, administration, plans, directs, and
infrastructure since 1998. In his role, and a member of the Holden coordinates, the administrative
he is responsible for coordinating Comprehensive Cancer Center since operations and activities of the HCCC
the shared research resources and 2007. including both research and clinical
working closely with the directors activities. Laubenthal facilitates
of these facilities to assure they are He has a remarkable record of interactions with the UI Hospitals
serving the needs of HCCC members. accomplishments related to clinical and Clinics and the Carver College
He serves on the faculty advisory research team leadership in that of Medicine to enhance clinical and
committees of the majority of shared period of time, and is an emerging basic research productivity. He serves
research resources supported leader in the field of clinical cancer as liaison with other departments,
by the HCCC. He also monitors research both institutionally and colleges, and outside organizations.
usage of shared research resources nationally. He works closely with senior
and makes recommendations to leadership to assure coordination and
the shared resource resources Dr. Milhem is deputy director for communication related to cancer
based on their performance. Dr. clinical cancer services in hte Holden oriented clinical service, research
Lubaroff explores the need for and Comprehensive Cancer Center. In and education. He manages all fiscal
development of new shared research this role he leads the development activities, including coordination of
resources by periodically surveying of better clinical services to help the annual budget process (operating
HCCC membership to document cancer center achieve its goals and to and capital), analysis of income
shared facility activities and unmet facilitate clinical cancer research and and expenditures, projections for
needs. His responsibilities include activities. He is leading many efforts annual budget requests, fiscal
developing, coordinating and to improve workflow for clinician reports, equipment and supplies,
maintaining research educational researchers and improve processes. maintenance, and assisting with and
programs for members including overseeing the grants management
seminars and conferences, and a process. He is administratively
program of visiting research scientists responsible for the administration
and lecturers. He coordinates the of the grant application process and
monthly HCCC Forum. Lubaroff works the conduct of research activities in
closely with HCCC administrative the HCCC including oversight of the
staff in oversight of shared research shared core resources. This includes
resource activities. Dr. Lubaroff is approximately $54.7 million in direct
a member of the HCCC Executive costs of which approximately 14.4
Committee and Associate Directors million is managed directly by the
Committee Cancer Center.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
22 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Research Programs
Cancer Immunology and Immunotherapy
AB OUT TH E P ROGRA M L EA DERS HIP
The Cancer Immunology and Immunotherapy Program consists of faculty
investigators who are linked by common research interests in the functioning
of the immune system, and how that system can be manipulated to help
prevent or treat cancer and complications of cancer. The investigators in this
program are working on problems that extend from fundamental molecular
questions to those involving how recent advances in basic immunology can be
translated into clinical utility for the treatment of cancer. ZUHAIR K. GAIL A.
BALLAS, MD BISHOP, PHD
Professor of Internal Professor of
Although many of investigators in the Cancer Immunology and Medicine Microbiology and
Immunotherapy Program are pursuing related questions, the individual Internal Medicine
research programs are diverse, allowing researchers in this program to attack
basic biologic issues, and develop new clinical therapies, from many angles.
Model systems being studied range from an evaluation of signaling properties
of T and B cells, to increasing the efficacy of vaccines and immunotherapy
in living animals, through the conduct of novel clinical trials related to
cancer immunotherapy. Clinical applications, as a direct result of more basic
investigations, have arisen from within the group and it is expected that this will
continue.
Because of the diversity of research interests reflected within the membership
of the Cancer Immunology and Immunotherapy Program, a wide range of
technologies and approaches are available to investigators. Each of our
investigators benefits from interactions with others in the program, as well
as members of additional Cancer Center programs, resulting in a synergism
yielding new insights, perspectives, and collaborative efforts.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
23
CHANGING MEDICINE. CHANGING LIVES.
Cancer Signaling and Experimental
Therapeutics Program
ABOUT THE P RO G RA M L EA DERS HIP
The overall organizational goal of the Cancer Signaling and Experimental
Therapeutics Program is to facilitate the application of recent advances in
our understanding of cell signaling, cell cycle control, and apoptosis, to the
development of new pharmacologic approaches to cancer prevention and
therapy.
Investigators in this program are working on problems that extend from
ALIASGER K. YATIN M.
fundamental molecular questions involving signaling pathways to those SALEM, PHD VYAS, MD
involving the design of novel compounds based on our growing knowledge of Associate Professor Professor of
of Pharmaceutics Pediatrics
molecular aspects of cell biology. Such laboratory scientists collaborate with
other members of the Program who are clinical investigators with a broad
range of backgrounds and expertise in performing innovative clinical cancer
trials.
The program includes basic and clinical investigators from multiple
departments at the University of Iowa, and has members who have primary
appointments in the Colleges of Medicine, Pharmacy, and Liberal Arts.
Kimberly Leslie, MD at work in her laboratory.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
24 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Tumor Imaging Program
AB OUT TH E P ROGRA M L EA DERS HIP
The goal of the Imaging Program is to foster interdisciplinary research that
integrates modern medical imaging techniques into basic, translational, and
clinical cancer research studies. The methodologies will include computed
tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron
emission tomography (PET), gamma scintigraphy, optical imaging, and
autoradiography. Metabolic imaging extends the capability of imaging well
beyond anatomy. It includes imaging blood flow, vascular permeability, MICHAEL JOHN
metabolic rates (glucose, oxygen, DNA synthesis, protein synthesis, membrane GRAHAM, MD, BUATTI, MD
PHD Professor and Chair,
synthesis), receptor distribution and density (estrogen, testosterone, Professor of Radiation Oncology
somatostatin), apoptosis, angiogenesis, cell trafficking, and reporter gene Radiology
activation. Members of the imaging program are working in all these areas. The
importance of having an Imaging Program is that it brings these investigators
together to collaborate, and share ideas, imaging strategies, and data analysis
methods.
The Imaging Program has the following specific areas of focus:
• Metabolic assessment of response
to therapy
• Iodine symporter as a reporter
gene and as a novel therapy
• Cell trafficking
• Development of new
radiopharmaceuticals
• Development of novel analysis
methodologies
Eric Hoffman, MD works with students and
staff in the Magnetic Resonance Research Facility.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
25
CHANGING MEDICINE. CHANGING LIVES.
Free Radical and Cancer Biology
Program
ABOUT TH E P RO G RA M L EA DERS HIP
For many years it has been recognized that many agents used to treat
cancer (i.e., radiation and chemotherapy agents) cause oxidative stress that
contributes to the mechanism by which they kill cancer cells as well as damage
normal tissues. Recently, it is becoming increasingly clear that metabolic
oxidation/reduction (redox) reactions are also altered in cancer vs. normal
cells. The current consensus is that cancer cells may exist in a chronic state
of metabolic oxidative stress that may represent a significant underlying DOUGLAS R. FREDERICK E.
mechanism contributing to malignancy. A unifying goal of the investigators SPITZ, PHD DOMANN, JR.,
Professor of PHD
in the Free Radical Cancer Biology Program is to utilize a comprehensive Radiation Oncology Professor of
understanding of redox biology to develop novel biochemical rationales Radiation Oncology
for improving cancer therapy taking advantage fundamental differences in
oxidative metabolism between cancer vs. normal cells.
The researchers in the Free Radical Cancer Biology Program (FRCBP) focus
on studying the biological consequences of inherent differences in redox
metabolism between cancer vs. normal cells to determine the role that
redox reactions play in cancer phenotypic changes relevant to cell growth,
differentiation, signal transduction, metastasis, functional molecular imaging,
and cancer therapy. A unifying goal of the program is to utilize a comprehensive
basic science understanding of cancer cell redox biology to develop novel
biochemical rationales for improving cancer therapy. Three overlapping
themes exist within the program.
Theme 1 Theme 2 Theme 3
Understanding the role of redox Understanding the role of redox Exploring the role of oxidative stress
biochemistry in regulation of genetic regulation in cell biology. Within this in cancer therapy outcomes. Within
and epigenetic gene expression theme are focus groups exploring this theme are focus groups exploring
pathways relevant to cancer biology. the effects of intracellular redox the role of manipulating oxidative
Within this theme are focus groups environmental changes on the stress to improve cancer therapy
exploring redox and gene expression cell cycle, and on invasion and as well as using imaging of oxidative
globally, as well as gene expression metastasis. metabolism as an approach to
of key redox molecules such as monitor and guide therapy.
glutathione, thioredoxin, SOD, and
AP2.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
26 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Cancer Epidemiology Program
AB OUT TH E P ROGRA M L EA DERS HIP
The overall goal of the Cancer Epidemiology Program is to save lives by
increasing our understanding of what causes cancer, promoting cancer
prevention behaviors and early detection and treatment, and developing
improved diagnostic tests and treatments. When cancer cannot be prevented,
we are also interested in research that will extend the quantity and quality of
life for the cancer survivor.
CHARLES F. LYNCH, MD, PHD
A major strength of the Cancer Professor of Epidemiology and Pathology
Epidemiology Program is its extension
beyond the walls of the medical
center, as its primary research
population is residents across the
state of Iowa. This is based on the role
played by the University of Iowa in
public health across Iowa, including
Barcey Levy, MD, PhD cancer epidemiology. Members of
the Cancer Epidemiology Program
are responsible for the State Health Registry of Iowa (SHRI), Iowa’s statewide
cancer surveillance program that is part of the Surveillance, Epidemiology,
and End Results (SEER) Program of the National Cancer Institute (NCI). This
resource allows researchers in the Cancer Epidemiology Program to perform
outstanding population-based cancer research. Information gained from these
studies can then be applied to other states and other populations.
The Cancer Epidemiology Program has three focus areas.
• Cancer Etiology
• Cancer Health Services and Outcomes
• Cancer Prevention and ControlABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
27
CHANGING MEDICINE. CHANGING LIVES.
Cancer Genomics and Cell Growth Program
ABOUT TH E P RO G RA M L EA DERS HIP
Research in the Cancer Genomics and Cell Growth Program focuses on genetic
and molecular events controlling normal versus malignant cell proliferation,
differentiation and survival. The overall goal of the program is to define
biologically significant genetic and molecular alterations in tumor cells so that
information can be used to more effectively detect and treat human cancers.
There are two major overlapping themes within the umbrella of the Progam’s
research. DAWN E. SIEGFRIED
QUELLE, PHD JANZ, MD, DSC
Associate Professor Professor of
Theme 1 of Pharmacology Pathology
Genomic organization and cancer gene expression/analysis
Theme 2
Cell growth, differentiation, survival and transformation.
Major accomplishments of the Cancer Genomics and Cell Growth Program
over the past funding period are best reflected by its identification and
characterization of novel cancer genes and/or biomarkers, development of
novel animal tumor models to discover and assess cancer gene function in
vivo, and increasing collaboration as demonstrated by coalescence of program
members into effective working groups. Key examples of intraprogrammatic
research collaborations include a) studies revealing the role of chromatin
binding proteins (such as RPA, DNA polymerases, HP1, transcription factors)
in gene expression and how that impacts the cancer phenotype, b) studies
defining basic mechanisms of viral infection and replication, and how that
leads to cell transformation, and c) the discovery and subsequent functional
analysis of novel genetic pathways of carcinogenesis. There are numerous
past and present productive collaborations both between members of the
Program, and with members of other Cancer Center programs. There are
currently 16 NIH and NCI funded projects involving multiple Program members
and/or HCCC members from other programs serving as co-Investigators. The
program consists of 36 members from 12 departments (8 basic science and 4
clinical departments) and 5 Colleges. Peer-reviewed, research funding for this
program totals $8,449,398 with $2,583,657 coming from the NCI.
Members of the Program have 300 cancer-related publications with nearly
30% collaborative publications (17% intra-programmatic, 12% inter-
programmatic) during the last grant period.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 28 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
29
CHANGING MEDICINE. CHANGING LIVES.
Core Facilities and Shared Resources
The Holden Comprehensive Cancer Center provides Center members with access to the services
and resources of our core facilities. The facilities provide quality products and services that enhance
the research efforts of Cancer Center investigators to foster basic and translational research.
Members of the Cancer Center with peer-reviewed, funded projects are the primary beneficiaries of
these core resources.
The core facilities within the Holden Comprehensive Cancer Center are funded by a combination
of funding from the Cancer Center Support Grant, Institutional support, other University of
Iowa sources and charge-back for services. David Lubaroff, PhD, associate director for research
infrastructure oversees these cores.
Clinical Trials Support Core
• Clinical Trials Data • Clinical Trials Translational
• Clinical Trials Regulatory • Protocol Development and Monitoring
Cancer Center Support Grant
• Clinical Trials Support Core • Gene Transfer Vector Core
• Bioinformatics Core • High Throughput Screening Core
• Biostatistics Core • Population Research Core
• Central Microscopy Research Facility • Radiation and Free Radical Research Core
• DNA Core • Small Animal Imaging
• Flow Cytometry Core • Tissue Procurement Core
Lymphoma SPORE Grant Other Resources
• Biospecimens • Molecular Pathology Resource
• Biostatistics and Bioinformatics • Proteomics Resource
• Clinical Research • Drug Discovery ResourcesUNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
30 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Clinical Trials Support Core
PUR P OSE S E RV I C E S L EA DERS HIP
The Clinical Trials Support Core • Routing of protocols through the University of Iowa
(CTSC) provides administrative Institutional Review Board or Western Institutional
services and data management Review Board and the appropriate regulatory
to all members of the Holden committees
Comprehensive Cancer Center who
• Providing expertise in coordination of clinical trial
conduct clinical studies.The CTSC is activities (recruitment of patients, determining BRIAN K. LINK,
a shared resources and is designed eligibility, obtaining consent, scheduling procedures, MD
to facilitate the conduct of high- Director
coordinating patient care needs, managing data
quality clinical and translational collection)
cancer research and is composed
• Serving as liaison to pharmaceutical companies,
of dedicated staff with expertise in
governmental regulatory agencies and other outside
protocol management and study
vendors
coordination.
• Budget writing and billing
• Assisting investigators with annual reviews, protocol
modifications and reporting of adverse events
• Providing assistance with collection and processing
blood and tissue samples for translational research
• Listing of all current clinical trials in the clinical trials
booklet
The Holden Comprehensive Cancer Center is also
an active participant of seven National Cooperative
Groups and investigators within the Center enroll over
550 patients on clinical research studies each year. The
National Cooperative Group Trials that are involved within
the Holden Comprehensive Cancer Center include:
• Cancer and Acute Leukemia Group B (ALLIANCE)
• National Surgical Adjuvant Breast Project (NSABP)
• Eastern Cooperative Oncology Group (ECOG)
• Collaborative Ocular Melanoma Study (COMS)
• Children’s Oncology Group (COG)
• Gynecological Oncology Group (GOG)
• Radiation Therapy Oncology Group (RTOG)
The Clinical Trials Support Core is currently staffed by
approximately 32 staff members.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
31
CHANGING MEDICINE. CHANGING LIVES.
Bioinformatics Core
PUR POS E S E RV ICES L EA DERSH IP
To provide bioinformatics support for Assistance is available on all types of projects, ranging
Cancer Center investigators in the from clinical trials to basic science experiments. Early
design, data collection/archiving and consultation during the design of a study may be
analysis of high-throughput genomics especially beneficial.
assays in cancer research projects. • Consultation on study design, selection of technology
platforms and formulation of hypotheses THOMAS L.
CASAVANT, PHD
• Specification of appropriate software tools and Director
methods for data analysis
• Database creation (DNA sequence, RNA expression,
proteomics, etc.)
• Protocol development
• Information technology consultation
• Data and experiment analysis
• Assistance in preparation of manuscripts
• Education and training
Biostatistics Core
PUR POS E S E RV ICES L EA DERSH IP
To provide statistical support for Assistance is available on all types of projects, ranging
Cancer Center investigators in the from clinical trials to basic science experiments. Early
design, analysis, and reporting of consultation during the design of a study may be
cancer research projects. especially beneficial.
• Consultation on study design, selection of outcome
variables and formulation of hypotheses
BRIAN J. SMITH,
• Specification of appropriate methods of data analysis PHD
Director
• Protocol development
• Generation of randomization schedules
• Data analysis
• Assistance in preparation of manuscripts
• Education and training.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
32 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Central Microscopy Research Facility
PUR POS E S E RV I C E S L EA DERS HIP
The Central Microscopy Research • Scanning electron microscopy
Facility provides instrumentation
• Transmission electron microscopy
and technical assistance to research
programs involving the use of • Light microscopy
scanning and transmission electron • Laser capture microdissection
microscopy, light and confocal
• Confocal microscopy RANDY A.
microscopy, scanning probe NESSLER, BGS,
microscopy, freeze fracture and x-ray • Multi-photon microscopy MBA
Director
microanalysis. • Cryo-techniques
• Elemental analysis
• Atomic force microscopy
• Bioluminescence microscopy
The facility also provides all solutions, supplies and
training necessary for investigators involving microtomy
including:
• Specialized staining and
embedding techniques
• Negative staining
• Metal coating
• Autoradiography
• Cryo-fixation
• Cryomicrotomy
• Enzyme-cytochemistry
• Immunocytochemistry
• Morphometry Scanning electron microscopy.
• StereologyABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
33
CHANGING MEDICINE. CHANGING LIVES.
DNA Core
PUR POS E S E RV ICES L EA DERSH IP
The purpose of the DNA Facility is • DNA Microarrays (Affymetrix GeneChip system and
to provide a centralized resource for Custom DNA microarrays using slide format)
access to state-of-the-art equipment
• Real-time PCR
used in DNA sequence and transcript
analysis. The DNA Facility strives to • DNA Sequencing (Sanger dideoxy sequencing using
provide high quality services with capillary-based instruments and genomic sequencing
KEVIN
rapid turnaround and support their using the Roches 454 and ABI SOLID instruments KNUDTSON, PHD
services with well trained personnel Director
• Synthetic Oligonucleotide
that are able to consult with users
• Molecular biology computing including custom
on how they may best utilize their
nucleic acid analysis, microarray analysis and genomic
services. The DNA Facility continues
sequence assembly/analysis.
to evaluate and update their services
so they remain cutting-edge, and • Bioanalyzer to assess nucleic acid quality and quantity
provide new services as necessary to
continue to meet the needs of Center
investigators.
Kevin Knudtson, PhD gives a tour of the core during a STEM
education program.UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
34 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Flow Cytometry Core
PU R POS E S E RV I C E S L EA DERS HIP
The Flow Cytometry Core is located In addition to identification and isolation of various cell
in the Eckstein Medical Research populations using antibodies, flow cytometry can analyze:
Building (EMRB). The facility has one • Cell proliferation response to drugs or treatments, such
magnetic-based and six laser-based as those used in chemotherapy
instruments whose major purpose
is the identification and isolation of • Cell physiological properties, such as calcium flux and
pH ZUHAIR K.
various cell populations. The laser- BALLAS, MD
based instruments accomplish • DNA content and integrity Director
this by the use of antibodies to • Transfection markers such as GFP and mCherry
which various colors or dyes have
been attached and are directed at Offline data analysis using FlowJoTM, CellquestTM, and
molecules known to exist on the ModFITTM can be done through the facility’s system of
cell surface. By using several colors networked computers. Investigators equipped with IBM
attached to different antibodies, or Mac-compatible PCs can perform analysis at their
one can identify and purify cells that laboratories or offices by accessing data through the
express any given configuration of Facility’s dedicated 1.5 terabyte file server.
various molecules.
The facility provides scientific and technical personnel
who are available for consultation in designing
experimental protocols. Cell preparation protocols and
publication quality output are available upon request.
A student is trained on instrumentation in the core.ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
35
CHANGING MEDICINE. CHANGING LIVES.
Gene Transfer Vector Core
PUR POS E S E RV ICES L EA DERSH IP
The Gene Vector Core assists The University of Iowa Carver College of Medicine GTVC
researchers interested in developing brings together investigators interested in developing and
and using viral vector construction. using, viral and non-viral vectors for gene transfer with
The core utilizes molecular biology specialists in the area of vector construction by:
techniques to engineer and produce • Consultation with the principal investigator to plan
viral and non-viral vectors in and develop transfer vectors to fit individual projects BEVERLY L.
quantities necessary for gene transfer requirements DAVIDSON, PHD
in research experiments or preclinical Director
studies. Core staff works closely with • Assist investigators with troubleshooting existing
investigators to plan and develop projects
gene transfer vectors to fit individual • Design and development of novel vectors
project requirements. • Develop novel methods of virus production such as
the RapAdTM System for adenovirus production
• Generation of RNAi expression vectors
• Purify, concentrate, and perform quality control on
preparations of recombinant adenovirus, adeno-
associated virus (AAV), moloney murine retrovirus,
lentivirus, baculovirus, and vaccinia virus
• Maintain and distribute standard cell lines and stocks
of recombinant reporter virusesUNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
36 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
High Throughput Screening Core
PUR POS E S E RV I C E S L EA DERS H IP
Initiated by the Vice President A robotic platform is available with 8-independent
for Research and the Holden channels and a 384 channel pipetting head. A liquid
Comprehensive Cancer Center handling robot is also equipped with on-board incubators
through collaboration with multiple (4 plates) and two positions for incubation/chilling of
departments, and housed in stock solutions.
the College of Pharmacy, the
MENG WU, PHD
High Throughput Screening, An integrated Perkin Elmer Envision Multimode high Director
Target Validation and Biomarker speed plate readed for use with detection is equipped
Identification Resource is aimed at with filters and monochromators. The plate reader,
pharmacologic characterization of controlled through the integrated software, supports
new molecular entities in enzyme, fluorescence, time-resolved flouorescence, fluorescence
receptor and cell-based systems, polarization, time-resolved FRET, absorbance and
including potency, intrinsic activity, specialized screening technologies including AlphaScreen,
selectivity, specificity, and off-target DELFIA and LANCE. The Envision is also equipped with
effects. This activity also includes two photomultipliers and a dedicated uHTS laster for high
the identification and validation/ speed AlphaScreen.
qualification of biomarkers for
target activation/inhibition, proof- The laboratory is also equipped with a five-color Roche
of-concept, efficacy and safety. An Lightcycler 480 II system, allowing for secondary
example is the use of high throughput confirmation of hits binding to a purified target using
screening for the discovery of novel differential scanning fluorimtetry.
pre-therapeutic lead molecules
directed at neurological applications. Two small molecular libraries are currently available. The
Strong leadership and multiple pilot Spectrum Library consists of 2,320 structurally diverse
grants have led to a large number of compounds including marketed and experimental drugs
collaboration exploratory projects in and natural products. A larger collection houses 50,000
the very short time that the center small molecules representing a wide swath of chemical
has been functional. space, optimized to be “drug-like.”
Management of compound library plates and screening
data is done through M-Screen, a web-accessed
academic database for analysis and curation.You can also read
